New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:04 EDTLGNDLigand says LGD-6972 well-tolerated in Phase 1 study
Ligand Pharmaceuticals announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligandís novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Associationís 74th Scientific Sessions meeting underway in San Francisco. Highlights of the single-ascending dose trial involving a total of 56 subjects include: LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events. LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of approximately 50 hours, supporting once-daily dosing. After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes. Fasting plasma glucose was reduced by 57 mg/dL in subjects with type 2 diabetes, suggesting a robust response in this acute study.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:33 EDTLGNDGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
July 22, 2014
13:17 EDTLGNDLigand reports partner SAGE receives fast track designation for SAGE-547
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use